SLC5A2 and hepatocellular carcinoma: It turns out this agent may also be useful to treat HCC, as Canagliflozin was shown to disrupt SGLT2-expressing liver cancers by reducing glucose uptake, inhibiting glycolytic metabolism, and attenuating proangiogenic activity (Kaji et al., 2018).